Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement

PurposeThe use of neoadjuvant anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has not been extensively explored. The current case report highlights the notable pathological complete response (pCR) achieved following neoadjuvant brigatinib therapy in a patient with stage IIIA ALK-p...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Hayoung Seong, Soo Han Kim, Mi Hyun Kim, Jeong Su Cho, Ahrong Kim, Jung Seop Eom
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	lung cancer anaplastic lymphoma kinase-tyrosine kinase inhibitor brigatinib neoadjuvant treatment case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1343238/full